Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy

Abstract

1 months (IQR 16.3-65.1 months), respectively (P < 0.001). Of the 91 patients developing diabetes mellitus, 16 were ever and 75 were never TNF␣ inhibitor users, yielding incidence rates of 8.6 and 17.2 per 1,000 person-years (P ‫؍‬ 0.048), respectively. Adjusting for covariates, the hazard ratio for incident diabetes mellitus in TNF␣ inhibitor users was 0.49 (95% confidence interval 0.24 -0.99, P ‫؍‬ 0.049) compared to the never users. Conclusion. In this inception RA cohort, anti-TNF␣ use was associated with a 51% reduction in risk of developing diabetes mellitus.

Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

“…In another study among patients with RA or psoriasis, the adjusted risk of T2DM was lower for individuals starting a TNF-a antagonist compared with initiation of other nonbiological disease-modifying antirheumatic drugs [85]. These data were confirmed in another cohort of RA patients for whom anti-TNF-a therapy was associated with a 51% reduction in risk of developing T2DM [86].…”

The Effect of Hydroxychloroquine Treatment on Blood Sugar Level, Serum Lipid Profile and the Retina in Systemic Lupus Erythematosus Patients

“…Several authors have also approved that the hypolipidemic effect of HCQ is due to its systemic inflammation control [27].…”

Metabolic syndrome in rheumatoid arthritis

“…Antohe и соавт. [138], использова-ние ингибиторов ФНОα (адалимумаб, этанерцепт, го-лимумаб, ИНФ) у 1587 пациентов с РА ассоциирова-О б з о р ы [129] Адипонектин ↓ Лептин ↑ Примечание. ↔ -не изменялся, ↑ -увеличивался, ↓ -снижался.…”